Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

TELA Bio shares hold as analyst reiterates price target

EditorAhmed Abdulazez Abdulkadir
Published 22/05/2024, 09:46 pm
TELA
-

On Wednesday, Canaccord Genuity maintained a positive stance on TELA Bio, Inc. (NASDAQ: NASDAQ:TELA), reaffirming a Buy rating and a price target of $14.00. The firm's commentary highlighted the recent executive changes within the company as a strategic move to enhance sales operations. TELA Bio announced the appointment of Greg Firestone as the new Chief Commercial Officer (CCO) on Tuesday, replacing the former CCO Peter Murphy, who was terminated without cause on May 19th.

Greg Firestone, who has been with TELA Bio since 2017 and previously served as the company's Chief Business Officer, is expected to leverage his extensive experience in strategy and partnership development to drive deeper penetration into Group Purchasing Organizations (GPOs) and Integrated Delivery Networks (IDNs). Firestone's strategic customer relations background and direct involvement in cultivating key GPO and IDN relationships are seen as critical assets as TELA Bio focuses on executing contracts within these networks through its sales team.

The transition comes after TELA Bio spent 2023 enhancing its salesforce to prepare for the next growth phase. The appointment of Firestone aligns with the company's commercial strategy, which is pivoting from the early commercialization phase to a more relationship and execution-focused approach. Firestone brings over 35 years of experience in the healthcare industry, including founding his own IDN, which contrasts with Peter Murphy's background in sales and marketing.

Murphy, who had been TELA Bio's CCO since 2020, brought valuable expertise to the company's early commercial efforts. His experience included various sales management roles at other healthcare companies prior to joining TELA Bio. However, as the company's growth strategy evolves, the leadership change is seen as a move to align the commercial team's expertise with the current objectives.

TELA Bio's strategic focus on GPO and IDN contract execution is a key element of its growth plan for the year. With Firestone at the helm of the commercial organization, Canaccord Genuity's reiterated Buy rating and price target suggest confidence in the company's direction and potential for sales growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.